Addiction Treatment
Addiction Treatment RSS Feed RSS

Co-Occurring Addiction and PTSD

May 21, 2019
Dolores Vojvoda, MD
Dolores Vojvoda, MD Dolores Vojvoda, MD
Assistant Professor of Psychiatry, Yale School of Medicine

Dr. Vojvoda has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Individuals who have PTSD have a high risk of developing other disorders, including substance use disorders (SUDs). Studies have shown that both in the veteran and non-veteran populations, these numbers are high.
Read More

Oral vs Extended-Release Naltrexone for Opioid Use Disorder

May 21, 2019
Jessica Goren, PharmD.
Jessica Goren, PharmD. Dr. Goren has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Extended-release (XR) naltrexone (Vivitrol) is FDA approved for opioid use disorder and has shown efficacy in several trials. It works best for patients who have already successfully detoxed from opioids and who are highly motivated to abstain. But what about oral naltrexone?
Read More

Does Extended-Release Naltrexone Worsen Psychiatric Symptoms?

May 21, 2019
Brian Frankel, MD.
Brian Frankel, MD. Dr. Frankel has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Extended-release (XR) naltrexone (Vivitrol) is an injectable version of naltrexone that lasts for 4 weeks and is FDA approved for opioid use disorder (OUD). Although effective, there is some concern that XR naltrexone may cause or worsen psychiatric symptoms because of its opioid blockade.
Read More

Assessing Traumatic Brain Injury in Patients with Substance Use Disorders

February 27, 2019
John D. Corrigan, Ph.D, ABPP
John D. Corrigan, Ph.D, ABPPJohn D. Corrigan, Ph.D, ABPP

Professor at Ohio State University and Director of the Ohio Valley Center for Brain Injury Prevention and Rehabilitation. Editor-in-Chief, Journal of Head Trauma Rehabilitation. Dr. Corrigan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational or other activity other interests in any commercial companies pertaining to this educational activity.

We don’t have definitive general population rates, but several statewide surveys suggest that perhaps 20% of adults have had at least one TBI with loss of consciousness in their lifetime. In studies done in addiction treatment settings, that number is more like 50%. And the prevalence is greater among clients in higher levels of care.
Read More

The FDA Campaigns Against Flavored Tobacco Products

February 27, 2019
Thomas Jordan, MD and Talia Puzantian, Pharm.D.
Thomas Jordan, MD Talia Puzantian, Pharm.D. Drs. Jordan and Puzantian have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Electronic cigarette use, or vaping, is becoming increasingly common. Companies manufacturing e-cigarettes advertise them as alternatives to conventional cigarettes and even a pathway to smoking cessation. However, the popularity of vaping has sky-rocketed in high schools across the country with adolescents becoming addicted to nicotine daily.
Read More

Does Augmenting Varenicline with Bupropion Work Better than Varenicline Alone?

February 27, 2019
Jessica Goren, PharmD.
Jessica Goren, PharmD. Dr. Goren has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
We have a good array of smoking cessation treatments to choose from, including nicotine replacement therapy (NRT), bupropion, and varenicline. Varenicline is the most effective monotherapy agent, somewhat better than bupropion and single-product NRT, and comparable to combination NRT.
Read More
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
Featured Video
Featured Podcast
Recommended

About

Shop Online

Newsletters

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.